TB-500 & the FDA: What the July 2026 PCAC Review Means

TB-500, a synthetic fragment of the protein thymosin beta-4, is not FDA-approved for any use. On July 23, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) voted on whether TB-500-related substances may be legally compounded under Section 503A. TB-500 was one of the six recommended; the FDA has not acted, so it is still not on the 503A bulks list. See full regulatory status. This guide explains the science, the regulatory timeline, and what the vote could change.

TB-500 & the FDA at a glance

• What it is: synthetic heptapeptide (Ac-LKKTETQ), residues 17–23 of thymosin beta-4
• FDA approval status: not approved for any human indication
• 503A status (current): removed from Category 2 effective April 22, 2026; PCAC recommended TB-500 for the 503A bulks list on July 23, 2026, but it is not on that list
• Key event: PCAC voted in favor of TB-500-related bulk substances on July 23, 2026 (advisory only)
• What's at stake: whether compounding pharmacies may legally use TB-500 under Section 503A
• Public comment docket: 91 Fed. Reg. 20465 (April 16, 2026); comments to PCAC due July 9, 2026

What is TB-500, and how is it different from thymosin beta-4?

TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ — seven amino acids corresponding to residues 17–23 of thymosin beta-4 (Tβ4), a naturally occurring 43-amino-acid protein found in nearly all human cells (BSCG anti-doping review, 2024). The acetylated leucine ("Ac-") at one end is intended to slow enzymatic breakdown.

This distinction matters more than most marketing copy admits. The LKKTETQ region carries the actin-binding motif of the parent protein, which is associated with cell migration, angiogenesis, and tissue repair. But TB-500 is only a fragment — it does not reproduce the full structure or the full biological repertoire of native thymosin beta-4.

The practical consequence: almost all published human clinical research has studied full-length thymosin beta-4, not the TB-500 fragment sold in research-chemical channels. When you see claims about "TB-500," many of the underlying studies actually used the complete 43-amino-acid peptide. We flag that gap throughout this guide because it directly affects how strong the evidence really is.

For a broader primer on the molecule itself, see our TB-500 complete guide. For the regulatory framework referenced below, see our 503A/503B compounding explainer.

How does thymosin beta-4 work in the research?

Thymosin beta-4 is best understood as an actin-sequestering peptide. It binds monomeric (G-) actin and influences the actin cytoskeleton, which governs how cells migrate, survive, and remodel tissue. Through these pathways, research in animal models has explored roles in wound repair, angiogenesis (new blood-vessel formation), and cardiac protection.

In a foundational study, thymosin beta-4 was shown to activate integrin-linked kinase (ILK) and the survival kinase Akt; after coronary-artery ligation in mice, treatment upregulated ILK/Akt activity and improved cardiac function (Bock-Marquette et al., 2004, Nature, 432:466–472). This is a mechanism paper in mice — not evidence that TB-500 protects the human heart.

On the vascular side, a review concluded that thymosin beta-4 promotes capillary formation and pericyte recruitment in development and injury models, while cautioning that "the underlying molecular mechanisms remain obscure" (Dubé & Smart, 2018, Expert Opin Biol Ther, 18(sup1):131–139). That hedge is important: even after two decades of study, the mechanistic picture is incomplete.

Consult your healthcare provider before drawing any personal conclusions from preclinical mechanism data.

What does the evidence actually show for TB-500?

Here the line between preclinical promise and human proof becomes sharp. Label each tier honestly:

Animal-model evidence (full-length thymosin beta-4):

• Thymosin beta-4 accelerated dermal wound closure in a rat model, increasing reepithelialization and collagen deposition (Malinda et al., 1999, J Invest Dermatol, 113(3):364–368).
• Thymosin beta-4 promoted angiogenesis and wound repair in both normal and aged rodents (Philp et al., 2004, Mech Ageing Dev, 125(2):113–115).

Human evidence (full-length thymosin beta-4, topical/ophthalmic):

• In a Phase 2 randomized, double-masked, placebo-controlled trial of severe dry eye, a thymosin beta-4 eye drop (RGN-259) produced a 35.1% reduction in ocular discomfort and a 59.1% reduction in corneal fluorescein staining versus vehicle at day 56 — but the trial enrolled only nine patients (Sosne et al., 2015, Cornea, 34(5):491–496). A small, single trial in the eye does not establish systemic efficacy.

Human evidence (the TB-500 fragment, injected, for athletic recovery): essentially none in the peer-reviewed literature. The popular use case — injecting TB-500 to speed musculoskeletal recovery — is not supported by controlled human trials.

So the accurate summary is: research in animal models suggests thymosin beta-4 may support wound healing and angiogenesis, limited human data exist for topical full-length Tβ4 in the eye, and rigorous human evidence for the injected TB-500 fragment is lacking. Anyone reading marketing claims should keep those tiers separate.

Is TB-500 FDA-approved? What is its current legal status?

No. TB-500 is not approved by the FDA for any human indication (BSCG, 2024). It has never completed the clinical-trial and approval process that any prescription drug must clear.

Because it is unapproved, TB-500's U.S. availability has historically run through two channels: products labeled "for research use only" (not for human consumption), and compounding pharmacies operating under Section 503A. The compounding pathway is exactly what the July 2026 PCAC review was about.

A quick framework. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a licensed pharmacy may compound a drug for an individual patient using a bulk drug substance only if that substance is FDA-approved, appears on the FDA's 503A Bulks List, or is the subject of an applicable USP monograph. To manage substances under evaluation, FDA created an interim policy that sorts nominated bulk substances into Category 1 (under evaluation, no significant safety risk identified, enforcement discretion) and Category 2 (substances FDA determined raise significant safety concerns) (FDA, Certain Bulk Drug Substances guidance).

Legal status varies by jurisdiction; consult a lawyer for binding advice.

What was the July 2026 PCAC review, and what did it mean for TB-500?

The Pharmacy Compounding Advisory Committee is the FDA's expert panel for compounding questions. Its central job here: advise FDA on whether a bulk drug substance should be added to the 503A Bulks List — the formal, rulemaking-based determination that a substance may be used in compounding under Section 503A.

The 2026 timeline, drawn from FDA and Federal Register actions:

• 2023: TB-500 and a group of other peptides were placed into 503A Category 2 based on FDA's safety concerns.
• April 15, 2026: FDA announced that 12 peptides — including TB-500 — would be removed from Category 2 within seven calendar days because the underlying nominations had been withdrawn (effective April 22, 2026).
• April 16, 2026: FDA published a Federal Register notice scheduling PCAC meetings (91 Fed. Reg. 20465).
• July 23–24, 2026: PCAC convened. On July 23, the committee discussed TB-500-related bulk substances (free base and acetate) alongside BPC-157, KPV, and MOTS-c. On July 24, it took up Emideltide (DSIP), Semax, and Epitalon (FDA PCAC meeting page, July 23–24, 2026).
• Before end of February 2027: A second PCAC meeting will consider five more peptides (GHK-Cu, Melanotan II, LL-37/cathelicidin, dihexa acetate, and PEG-MGF).

Why it mattered: the July 23 vote was an inflection point for legal access, and it went in TB-500's favor. The committee recommended adding TB-500 to the 503A Bulks List, alongside BPC-157, KPV, MOTS-c, Semax, and Epitalon; only emideltide (DSIP) was rejected (NCPA, July 31, 2026). That is a recommendation, not a rule: PCAC is advisory, the FDA makes the final call through notice-and-comment rulemaking, and TB-500 is not on the Bulks List today.

Members of the public could submit written comments to the docket. Comments received by July 9, 2026 were to be provided to committee members ahead of the meeting; comments by July 22, 2026 would still be considered by FDA. The docket is FDA-2025-N-6895, named as such in the meeting notice published April 16, 2026 at 91 FR 20465 (Federal Register, FR Doc. 2026-07361).

What are the safety and anti-doping considerations?

Because TB-500 is unapproved, there is no FDA-reviewed safety profile, no standardized dosing, and no manufacturing oversight for products sold outside the regulated supply chain. Purity, sterility, and actual peptide content of gray-market vials are unverified — a meaningful contamination and mislabeling risk. FDA's original 2023 Category 2 placement reflected the agency's view that these peptides raised significant safety concerns warranting further evaluation (FDA, Certain Bulk Drug Substances guidance).

On the human-evidence side, the available controlled data come almost entirely from topical/ophthalmic full-length thymosin beta-4 in small trials (Sosne et al., 2015, Cornea). The long-term safety of injected TB-500 in humans has not been established in controlled studies. A theoretical concern frequently raised about pro-angiogenic peptides is that promoting blood-vessel growth could be undesirable in the presence of occult tumors; this is a mechanism-based caution, not a demonstrated clinical outcome — no human oncogenicity data for TB-500 exist in either direction.

For athletes, the regulatory answer is unambiguous: thymosin beta-4 and TB-500 are prohibited at all times under the World Anti-Doping Agency (WADA) Prohibited List, classified under S2.3, growth factors and growth factor modulators, which names "Thymosin-ß4 and its derivatives e.g. TB-500" (WADA 2026 Prohibited List). BPC-157 sits elsewhere, under S0 (non-approved substances) — a distinction worth knowing, because S0 substances are Specified and S2 substances are not, though both are banned at all times. The U.S. Department of Defense has adopted the WADA prohibited categories, so service members are covered as well (BSCG, 2024).

Consult your healthcare provider before starting any peptide protocol, and consult a lawyer for binding advice on legal status.

How could the PCAC recommendation change access in NYC and elsewhere?

For now, nothing about the July 2026 review makes TB-500 an approved drug — approval is a separate, far higher bar. What the vote affects is the compounding question.

PCAC has recommended adding TB-500 to the 503A Bulks List. If the FDA agrees and completes rulemaking, licensed 503A pharmacies could compound it for individual patients with a valid prescription — a more controlled channel than research-chemical sales. Until that happens, nothing has changed: sanctioned 503A compounding of TB-500 remains off the table, and legitimate access stays limited to research and clinical-trial settings. The FDA is not obliged to follow the committee, and it has not said when it will decide.

NYC residents should also remember that New York State pharmacy and controlled-substance rules layer on top of federal law. Practitioner access, sourcing, and what a provider can legally offer may differ from the federal baseline. For peptide-curious New Yorkers, the most durable takeaway is to follow the verified-source and licensed-provider path rather than the gray market — regardless of which way the July vote goes.

Consult your healthcare provider before starting any peptide protocol; legal status varies by jurisdiction.

Keep reading: browse the full Safety library, or start from our Healing hub to see how this piece fits the wider picture. If you are weighing the two tissue-repair peptides against each other, our BPC-157 vs TB-500 comparison puts them side by side.

Frequently asked questions

Q: Is TB-500 FDA-approved in 2026? A: No. TB-500 (a synthetic fragment of thymosin beta-4) is not FDA-approved for any human indication, and the July 2026 PCAC review does not change that. The review concerns only whether TB-500 may be legally compounded under Section 503A — a separate question from drug approval. Approval would require completed clinical trials and an FDA marketing authorization, which TB-500 does not have. Consult your healthcare provider before considering any peptide.

Q: What is the FDA PCAC meeting on July 23, 2026? A: The Pharmacy Compounding Advisory Committee (PCAC) is the FDA's advisory panel on compounding. On July 23, 2026, it discussed TB-500-related bulk substances — alongside BPC-157, KPV, and MOTS-c — and advised the FDA to add them to the 503A Bulks List. Inclusion would permit pharmacy compounding under Section 503A; exclusion would keep it outside that framework. PCAC's role is advisory; the FDA makes the final decision, and it has not yet acted.

Q: Why was TB-500 removed from FDA Category 2 in April 2026? A: On April 15, 2026, FDA announced that 12 peptides, including TB-500, would be removed from 503A Category 2 within seven days (effective April 22, 2026) because the underlying nominations for the bulks list had been withdrawn by the nominators. Removal from Category 2 is procedural — it does not mean FDA endorsed TB-500. The substances were instead routed to PCAC review in July 2026 and February 2027.

Q: What is the difference between TB-500 and thymosin beta-4? A: Thymosin beta-4 is a natural 43-amino-acid protein. TB-500 is a synthetic 7-amino-acid fragment (Ac-LKKTETQ, residues 17–23) containing the actin-binding region. The fragment retains some actin-related activity but not the full structure or full biology of the parent protein. Critically, most published human research used full-length thymosin beta-4, not the TB-500 fragment.

Q: Is there human evidence that TB-500 works? A: Rigorous human evidence for the injected TB-500 fragment is lacking. The human data that exist come from small trials of topical/ophthalmic full-length thymosin beta-4 — for example, a 9-patient Phase 2 dry-eye trial (Sosne et al., 2015, Cornea). Animal models suggest thymosin beta-4 may support wound healing and angiogenesis, but those findings do not establish efficacy of injected TB-500 in humans. Discuss expectations with a healthcare provider.

Q: Is TB-500 banned in sports? A: Yes. Thymosin beta-4 and TB-500 are prohibited at all times under the World Anti-Doping Agency (WADA) Prohibited List, in the growth-factors category, for athletes in WADA-governed sport. The U.S. Department of Defense has adopted WADA's prohibited categories, so military service members are covered as well. Penalties for violations can be substantial.

Q: Can I get TB-500 from a compounding pharmacy right now? A: As of September 2026, TB-500's compounding status is still unsettled. PCAC recommended it for the 503A Bulks List on July 23, 2026, but that recommendation is advisory: TB-500 is not on the Bulks List, and it is not an FDA-approved drug. Whether any pharmacy can lawfully compound it depends on the evolving federal framework and your state's rules. Consult a licensed provider and, for binding legal questions, a lawyer.

References

1. Bock-Marquette I, Saxena A, White MD, Dimaio JM, Srivastava D. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016):466–472. PMID: 15565145. https://pubmed.ncbi.nlm.nih.gov/15565145/
2. Malinda KM, Sidhu GS, Mani H, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364–368. PMID: 10469335. https://pubmed.ncbi.nlm.nih.gov/10469335/
3. Philp D, Goldstein AL, Kleinman HK. Thymosin beta4 promotes angiogenesis, wound healing, and hair follicle development. Mech Ageing Dev. 2004;125(2):113–115. PMID: 15037013. https://pubmed.ncbi.nlm.nih.gov/15037013/
4. Sosne G, Dunn SP, Kim C. Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial. Cornea. 2015;34(5):491–496. PMID: 25826322. https://pubmed.ncbi.nlm.nih.gov/25826322/
5. Dubé KN, Smart N. Thymosin β4 and the vasculature: multiple roles in development, repair and protection against disease. Expert Opin Biol Ther. 2018;18(sup1):131–139. PMID: 30063849. https://pubmed.ncbi.nlm.nih.gov/30063849/
6. U.S. Food and Drug Administration. July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. FDA Advisory Committee Calendar; Federal Register notice 91 Fed. Reg. 20465 (April 16, 2026). https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
7. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks (503A Categories 1 and 2). https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
8. Banned Substances Control Group (BSCG). TB-500 — Status, Risks, and Bans in Sport and Military. 2024. https://www.bscg.org/blogs/single/tb-500-status-risks-and-bans-in-sport-and-military